Published in final edited form as:

Neurosci Lett. 2006 November 20; 408(3): 170–172.

Lack of association of two chromosome 10q24 SNPs with Alzheimer's disease

Ryan L. Minster, MSIS¹, Steven T. DeKosky, MD², and M. Ilyas Kamboh, PhD^{1,*}

¹ Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA

² Department of Neurology, University of Pittsburgh, Pittsburgh, PA

Abstract

Several groups have reported evidence of linkage on chromosome 10 to late-onset Alzheimer's disease (LOAD). In a recent scan of single nucleotide polymorphisms (SNPs) on chromosome 10, significant associations between the *rs498055* and *rs4417206* SNPs and risk of LOAD were observed. We examined the association of these two SNPs with LOAD risk in a large Caucasian American cohort comprising about 2,000 cases and controls. Neither SNP revealed significant association with LOAD risk or age-at-onset.

Alzheimer's disease (AD) is a neurodegenerative disorder with complex environmental and genetic involvement. Sequence variation in a few genes explains many cases of familial early-onset (age-at-onset [AAO] < 60 years) AD, but these cases account for a small fraction of total cases [14]. Only the association between *APOE* genetic variation and risk of late-onset AD (LOAD) has been replicated consistently. However, the *APOE* gene explains only part of the genetic variation associated with LOAD risk.

Several groups have observed linkage with risk of AD or related measures on chromosome 10 [6], but the identification of the LOAD gene on this chromosome remains elusive. A recent scan of chromosome 10 identified several potential single nucleotide polymorphisms (SNPs) associated with LOAD in four Caucasian case-control samples. Two SNPs, *rs498055* and *rs4417206*, revealed the most significant association in the combined sample ($p = 0.00004$ and $p = 0.0019$, respectively). SNP *rs498055* is located in an *RPS3A* homologue, and *rs4417206* is located in the *ALDH18A1* gene. They are approximately 41 kb apart, but in strong linkage disequilibrium [3]. The purpose of this study was to replicate the reported association in a fairly large case-control Caucasian American sample.

Case subjects for this study were Caucasian Americans with LOAD ($n = 1,138$; mean AAO 72.5 ± 6.3 [SD] years; 67.7% female; 24.1% autopsy-confirmed) recruited through the University of Pittsburgh Alzheimer's Disease Research Center. All cases were either evaluated clinically and satisfied criteria for probable or possible AD [7] or by autopsy and satisfied neuropathological criteria for definite AD [8–9]. The control subjects ($n = 945$, mean age at baseline 74.1 ± 6.2 years, 59.5% female, 1.7% autopsy-confirmed) were Caucasian Americans age 60 or above with no psychiatric or neurological disorders. This study was approved by the University of Pittsburgh Institutional Review Board.

The *rs498055* and *rs4417206* SNPs were genotyped by template-directed dye terminator incorporation assays detected with fluorescence polarization (TDI-FP). Polymerase chain reaction (PCR) primers for *rs498055* were 5' -CGCCAAATCCAGAAGATGA-3' and 5' -

* Corresponding Author: University of Pittsburgh, Department of Human Genetics, Pittsburgh, PA 15261, 412-624-3066, Fax: 412-383-7844, ikamboh@hgen.pitt.edu.

TTGGCAAGCCTTTTCTATGTC-3' ; the (reverse) internal primer for the dye terminator incorporation was 5' -CCTTTTCTATGTCTTTTCCAATGCT-3'. PCR primers for *rs4417206* were 5' -ATTTTGGGAAGGGCTCAGTG-3' and 5' -CAACCAGGTGCAAAGAGAAG-3' ; the (forward) internal primer was 5' -CACTGGCTTCTTTGATTTCAGG-3'. Previous publications' nomenclature gives the alleles as they appear on the top strand of chromosome 10 (A and C) [2–4]; here we give the alleles as they appear on the forward strand of *ALDH18A1* (T and G). PCR was completed with 2 ng template DNA.

APOE was genotyped as described previously [5].

Both case and control samples were present on every plate. To assess genotyping error rate, 10% of samples were selected at random and repeated.

Allele frequencies were determined by direct allele counting. Goodness of fit to Hardy–Weinberg equilibrium and differences in genotype and allele frequencies between cases and controls were examined using the χ^2 test. Genotype and allele frequencies for each SNP were also stratified by the presence of *APOE**4, by age at baseline in controls and AAO in cases and by diagnosis method (that is, clinically assessed or by autopsy); the frequencies of cases and controls were compared in each subgroup using the χ^2 test. The mean AAO for different genotypes was compared using one-way analysis of variance (ANOVA) and was adjusted for sex and *APOE**4 carrier status. To assess linkage disequilibrium (LD) between the two SNPs, we calculated D' and r^2 . We compared haplotype frequencies in cases and controls and examined the effect of haplotype on AAO, adjusted for sex and *APOE**4. All statistical calculations were completed using R 2.2.0 [13] with the genetics and haplo.stats packages attached.

Genotyping efficiency was 92.4% for *rs498055* and 88.2% for *rs4417206* with genotyping error about 1.2%. Genotype and allele frequencies in cases and controls for both SNPs are shown in Table 1. Genotype frequencies for *rs498055* did not deviate with statistical significance from those expected under Hardy–Weinberg assumptions. However, *rs4417206* did deviate in cases ($p = 0.024$), but not in controls ($p = 0.730$). The genotype frequencies of the various subgroups defined by *APOE**4 carrier status, AAO/age and diagnosis method did not significantly differ from Hardy–Weinberg equilibrium for either SNP. LD between the two SNPs was estimated as $D' = 0.87$ and $r^2 = 0.45$.

For neither SNP did genotype or allele frequencies differ with statistical significance between cases and controls. The minor allele frequency (MAF) of *rs498055* was 46.2% in cases and 46.9% in controls ($p = 0.900$). The MAF of *rs4417206* was 34.7% in cases and 33.3% in controls ($p = 0.147$). Differences within the *APOE**4-, AAO/age- and diagnosis-method-stratified subgroups were also non-significant (data not shown). No statistical association between haplotype frequencies and risk of LOAD was observed ($p = 0.773$).

Neither SNP had a statistically significant effect on AAO (*rs498055*, $p = 0.947$; *rs4417206*, $p = 0.780$), nor did the any of the haplotypes defined by the two SNPs (p -value range: 0.867–0.581).

Of the 1,412 SNPs examined by Grupe and colleagues [3], *rs498055* and *rs4417206* yielded the highest statistically significant results. Although there is strong LD between the two SNPs, the correlation between them is not very high. Our measures of LD ($D' = 0.87$; $r^2 = 0.45$) were similar to those determined by Grupe et al. ($D' = 0.98$; $r^2 = 0.43$) [3]. We were unable to verify the reported associations between *rs498055* and *rs4417206* and the risk of LOAD despite our sample of approximately 2,000 cases and controls from a single geographical location, a sample comparable to the combined approximately 2,000 cases and controls from three locations

reported on by Grupe et al. While the MAF of *rs498055* in our LOAD cases is very similar to the reported average frequency in U.S. cases (53.8% in our sample vs 54.3% in Grupe et al.'s; $p = 0.779$), it is higher in our controls than the U.S. controls reported by Grupe et al. (53.1% vs 47.3%; $p = 0.0014$). On the other hand, the MAF of *rs4417206* is similar in both control groups (33.5% vs 35.6%; $p = 0.180$), but slightly different in case groups (34.7% vs 31.2%; $p = 0.0197$). There is no clear explanation of this odd observation where the frequencies of one SNP were similar between the two case groups while the frequencies of the second SNP were similar between the two control groups. More importantly, the frequencies of the established risk factor—*APOE*—are similar between our case-control cohort (*APOE**4: 33.5% in cases and 11.2% in controls) and Grupe et al.'s (35.6% and 12.5%) [4]. Thus the difference in chromosome 10 SNPs does not appear to be due to population heterogeneity. The other possibility is non-random genotyping errors in cases or controls. However, our error rate was only 1.2% and randomly distributed in cases and controls.

While our study was in progress, Bertram et al. [2] completed an examination of *rs498055* in two family samples. They also did not see any association between this SNP and risk or AAO of AD. In a reply, Grupe et al. [4] proposed that the discrepant findings between their study and Bertram et al.'s [2] could be due to reduced statistical power in studies involving a family-based sample. They provided evidence for this by comparing the risk allele frequencies of *APOE* and *rs498055* between cases and controls in their case-control series and in their linkage family sample; indeed the differences in allele frequencies were much greater in the case-control series than in the family sample. However, our case-control cohort has *rs498055* frequencies quite similar to Grupe et al.'s family sample (and to Bertram et al.'s LOAD families), but our *APOE* frequencies parallel their case-control series. Furthermore, our case-control sample is equally powered to that reported by Grupe et al. Our study has 98% power to detect the reported odds ratio (OR) of 1.3 for the *rs498055* SNP and 83% power to detect the reported OR of 0.81 for the *rs4417206* SNP. Thus, the lack of association in our sample is not likely due to insufficient power.

The lack of association of *rs498055* in our large case-control sample and in two family samples [2] suggests that the sought chromosome 10 gene may not be present in this region. Notably, no significant association of *rs498055* was found in autopsied confirmed cases and controls by Grupe et al. [3], which would have been more convincing. Additionally we have examined five SNPs around the insulin degrading enzyme gene (*IDE*) located about 3 Mb proximal to the two SNPs examined in this study, and found no statistical evidence of association [10]. On the other hand, we have found suggestive associations with SNPs located in the *CHAT* and *PLAU* genes [11–12], which mark boundaries of an about 24 Mb region between 10q11.23 and 10q22.23, about 22 Mb proximal to the two SNPs studied here. Compelling evidence of the existence of a LOAD gene between 10q11.23 and 10q22.23 has also recently been provided using parent-of-origin information [1]. Additional comprehensive association studies are needed to identify the elusive chromosome 10 gene for LOAD.

Acknowledgements

This study was supported by National Institute on Aging grants AG13672 and AG05133.

References

1. Bassett SS, Avramopoulos D, Perry RT, Wiener H, Watson B Jr, Go RCP, Fallin MD. Further evidence of a maternal parent-of-origin effect on chromosome 10 in late-onset Alzheimer's disease. *Am J Med Genet B Neuropsychiatr Genet* 2006;141B:537–540. [PubMed: 16741936]
2. Bertram L, Hsiao M, Lange C, Blacker B, Tanzi RE. Single-nucleotide polymorphism *rs498055* on chromosome 10q24 is not associated with Alzheimer disease in two independent family samples. *Am J Hum Genet* 2006;79:180–183. [PubMed: 16773580]

3. Grupe A, Li Y, Rowland C, Nowotny P, Hinrichs AL, Smemo S, Kauwe JSK, Maxwell TJ, Cherny S, Doil L, Tavey K, van Luchene R, Myers A, Wavrant-De Vrièze F, Kaleem M, Hollingworth P, Jehu L, Foy C, Archer N, Hamilton G, Holmans P, Morris CM, Catanese J, Sninsky J, White TJ, Powell J, Hardy J, O'Donovan M, Lovestone S, Jones L, Morris JC, Thal L, Owen MJ, Williams J, Goate A. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer's disease. *Am J Hum Genet* 2006;78:78–88. [PubMed: 16385451]
4. Grupe A, Li Y, Rowland C, Hinrichs T, Holmans P, Hardy J, O'Donovan M, Owen MJ, Williams J, Goate A. Reply to Bertram et al. *Am J Hum Genet* 2006;79:183–184.
5. Kamboh MI, Aston CE, Hamman RF. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. *Atherosclerosis* 1995;112:145–159. [PubMed: 7772075]
6. Kamboh MI. Molecular genetics of late-onset Alzheimer's disease. *Ann Hum Genet* 2004;68:381–404. [PubMed: 15225164]
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984;34:939–944. [PubMed: 6610841]
8. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;41:479–486. [PubMed: 2011243]
9. National Institute on Aging, Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. *Neurobiol Aging* 1997;18:S1–S2. [PubMed: 9330978]
10. Ozturk A, DeKosky ST, Kamboh MI. Lack of association of 5 SNPs in the vicinity of insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease. *Neurosci Lett Epub ahead of print*. 2006
11. Ozturk A, DeKosky ST, Kamboh MI. Genetic variation in the choline acetyltransferase (CHAT) gene may be associated with the risk of Alzheimer's disease. *Neurobiol Aging* 2006;27:1440–1444.
12. Ozturk A, Minster RL, DeKosky ST, Kamboh MI. Association of tagSNPs in the urokinase–plasminogen activator (PLAU) gene with Alzheimer's disease and associated quantitative traits. *Am J Med Genet B Neuropsychiatr Genet Epub ahead of print*. 2006
13. R Development Core Team, R. A language and environment for statistical computing, R Foundation for Statistical Computing. Vienna, Austria: 2005.
14. Rocca WA, Hofman A, Brayne C, Breteler MMB, Clarke M, Copeland JRM, Dartiques J-F, Engedal K, Hagnell O, Heeren TJ, Jonker C, Lindesay J, Lobo A, Mann AH, Mölsä PK, Morgan K, O'Connor DW, da Silva Droux A, Sulkava R, Kay DWK, Amaducci L. EURODEM–Prevalence Research Group, The prevalence of vascular dementia in Europe: Facts and fragments from 1980–1990 studies. *Ann Neurol* 1991;30:817–824. [PubMed: 1838681]

Table 1

<i>rs498055</i>					<i>rs4417206</i>				
	Cases		Controls			Cases		Controls	
	<i>n</i>	(%)	<i>n</i>	(%)		<i>n</i>	(%)	<i>n</i>	(%)
<u>Genotype</u>					<u>Genotype</u>				
CC	300	(28.3)	237	(27.4)	TT	441	(44.3)	372	(44.2)
CT	541	(51.0)	445	(51.4)	TG	419	(42.1)	378	(44.9)
TT	219	(20.7)	183	(21.2)	GG	136	(13.7)	91	(10.8)
Total	1060	(100.0)	865	(100.0)	Total	996	(100.0)	841	(100.0)
<u>Allele</u>					<u>Allele</u>				
C	1141	(53.8)	919	(53.1)	T	1301	(65.3)	1122	(66.7)
T	979	(46.2)	811	(46.9)	G	691	(34.7)	560	(33.3)

Genotype and allele frequencies in cases and controls.